Celgene Corporation (NASDAQ:CELG) and the Lymphoma Study Association (LYSA) gave investors reason to raise a red flag today, as shares start to slip …
Celgene Corporation (NASDAQ:CELG) announced detailed results from the phase III SUNBEAM™ trial evaluating the efficacy and safety of ozanimod, a novel, oral, selective …
Cantor: CELG pipeline needs commercial juice; Cowen: Sarepta soars on strong Exondys 51 orphan launch.
Eric Schmidt worries CELG investors will further question franchises’ longevity in the 3Q earnings aftermath.
Cowen always deemed CELG’s failed drug a risky contender, welcomes GILD’s full approval for Yescarta.
Insider transactions can be the foundation of numerous trading strategies and signals. For example, we found that a strategy based on only top-ranked …
In a research report issued April 30, Canaccord Genuity analyst John Newman reiterated a Buy rating on Celgene Corporation (NASDAQ:CELG) with a price target …
In a research report published Friday, Piper Jaffray analyst Joshua Schimmer reiterated an Overweight rating on Celgene Corporation (NASDAQ:CELG) and raised the price …
Piper Jaffray’s healthcare analyst Joshua Schimmer weighed in with an update on Celgene Corporation (NASDAQ:CELG), as the company reported yesterday morning full fourth-quarter results and guidance. The analyst …
In a research report published today, J.P.
